Bcnu plus teniposide (vm26) as a 1st line chemotherapy for brain metastases regardless of the origin.

Twenty-nine patients with brain metastases regardless of the origin were treated with the combination of 1-3-bis-(2-chloroethyl)-1-nitrosourea (BCNU), 120 mg/m2 i.v. every six weeks, and teniposide (VM26), 100 mg/m2 i.v. on the days 1 and 2 of every three-week period. Five objective responses were obtained (17%), four of them being partial and one complete. The latter was observed in a patient suffering from breast cancer, and still remains free of the disease after three years follow-up. The median survival time for the whole group is 14.6 weeks. Twelve more patients (41%) had symptomatic improvement related to chemotherapy. The treatment was well tolerated and only mild and reversible toxicity was observed. A global 58% (17% plus 41%) symptomatic improvement was observed.